Chemclin Diagnostics Co., Ltd., (hereinafter referred to as "Chemclin Diagnostics" or "the company"), founded in 2007, is a leading Chinese diagnostics company engages in development, production, and sales of In Vitro Diagnostics (IVD) products with specialization in clinical immunoassays testing reagents and instruments utilizing chemiluminescent immunoassays (CLIA).
As the pioneer of Chinese clinical immunoassays industry,the largest sub sector of IVD industry, Chemclin diagnostics leveragesthe profound product development expertise in developing assays and automated systems on existing technology platforms, to apply the research and development knowhows to the proprietary next-generation technology platform ofLight-initiated Chemiluminescence Immunoassay (LiCA). Achieved through unprecedented integration of proprietary nanoparticle polymers, innovative light-initiated chemiluminescent signaling, wash-free immunoassay designsandautomation technologies, LiCA is a next-generationclinical immunoassays platform embodies a combination of precision, efficiency, and user-driven design. Chemclin Diagnostics hasdeveloped LiCAassays with wide coverage of disease panels and series of automated LiCA systemsacross key laboratory disciplines.The critical information derived fromLiCA systems navigatestreatment decision-makings for millions of peopleand numerous health conditions from infectious diseases to reproductive health to metabolic diseases and cancers.
Driven by core value of "Serving human health through innovation", Chemclin Diagnostics iscommittedto delivering results that drive better patient carethroughthe developmentofinnovative and cost-effective diagnostic productsandservesthebestinterestsofcustomers, employees, and shareholders.
| Full name | Chemclin Diagnostics Co., Ltd. |
|---|---|
| Abbreviations | Chemclin Diagnostics |
| Code | 688468 |
| Founded | 2007-05-10 |
| Listing | 2021-04-09 |
| Domicile | Beijing, China |
| Website | www.chemclin.com |
| ir@chemclin.com | |
| STAR Theme | Biomedicine |
| CSRC Sector | Medicine manufacturing |
| Has weighted voting rights structure? | N/A |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Earnings Per Share | 0.33 | 0.39 | |
| R&D expenditure as a % of operating revenue | 13.49% | 12.42% | 13.91% |
| Operating Revenue | 418.20 | 454.67 | 366.06 |
| Net Income | 117.02 | 140.59 | -424.25 |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Operating Revenue | 418.20 | 454.67 | 366.06 |
| Operating Costs | 300.34 | 312.69 | 785.03 |
| Operating Income | 136.85 | 159.73 | -412.41 |
| Pretax Income | 135.44 | 159.64 | -413.31 |
| Income Tax | 18.42 | 19.05 | 10.94 |
| Net Income | 117.02 | 140.59 | -424.25 |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Assets | |||
| Current Assets-Total | 702.34 | 709.50 | 574.80 |
| Non-current Assets-Total | 304.48 | 283.89 | 281.45 |
| Total Assets | 1,006.82 | 993.39 | 856.25 |
| Liabilities | |||
| Current Liabilities-Total | 104.73 | 115.09 | 78.44 |
| Non-current Liabilities-Total | 14.73 | 11.33 | 2.42 |
| Total Liabilities | 119.46 | 126.42 | 80.87 |
| Stockholder's Equity | |||
| Share Capital | 699.92 | 696.56 | 1,314.12 |
| Retained Profits | 187.44 | 170.42 | -538.73 |
| Total Owners' Equity | 887.36 | 866.97 | 775.38 |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Net Cash Flows-Operating | 151.95 | 201.27 | 147.68 |
| Net Cash Flows-Investing | -22.21 | -130.79 | -263.09 |
| Net Cash Flows-Financing | -111.19 | -44.61 | 32.53 |
| Name | No. of Shares Held (mn) | % of Shares Held |
|---|---|---|
| 宁波保税区英维力企业管理合伙企业（有限合伙） | 108.00 | 30.00% |
| 上海沛禧投资管理合伙企业（有限合伙） | 45.42 | 12.62% |
| 横琴君联致康投资企业（有限合伙） | 41.62 | 11.56% |
| LOYAL CLASS LIMITED | 26.51 | 7.37% |
| 深圳市平安置业投资有限公司 | 22.71 | 6.31% |
| 中金康瑞壹期（宁波）股权投资基金合伙企业（有限合伙） | 22.71 | 6.31% |
| 宁波保税区科倍奥企业管理合伙企业（有限合伙 | 18.00 | 5.00% |
| 嘉兴申贸叁号股权投资合伙企业（有限合伙） | 14.32 | 3.98% |
| 杭州创乾投资合伙企业（有限合伙） | 11.36 | 3.15% |
| 宁波梅山保税港区平盛安康股权投资基金合伙企业（有限合伙） | 11.36 | 3.15% |
| Triton Device HK Limited | 11.36 | 3.15% |
All information contained herein is provided by the underlying company itself and is for informational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. The Shanghai Stock Exchange does not guarantee its accuracy and reliability and shall under no circumstance be responsible or liable for any error or for any loss directly or indirectly arising from any inaccuracy or omission or from any decision, action or non-action based on or in reliance upon the information herein.
Users may view and download the information herein for personal and non-commercial use free of charge subject to the laws of the People's Republic of China and the Legal Statement. No part of the information herein may be copied, downloaded, stored in a retrieval system or transmitted in any form or by any means, rented, displayed, performed, reproduced, photocopied, altered, sold, broadcast, published or otherwise in whole or in part in any manner for commercial purposes, without the prior written consent of the Shanghai Stock Exchange.
Users are hereby reminded that the Legal Statement represents your legally binding agreement with the Shanghai Stock Exchange. By accessing or using this website, you are also signifying your agreement with and acceptance of all the contents in the Legal Statement. The Shanghai Stock Exchange reserves the right to amend and interpret the Legal Statement.